These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 8241606)

  • 1. Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.
    Leake A; Ferrier IN
    Drugs Aging; 1993; 3(5):408-27. PubMed ID: 8241606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer and Lewy body type: comparison with Parkinson's disease and severity correlations.
    Leake A; Perry EK; Perry RH; Jabeen S; Fairbairn AF; McKeith IG; Ferrier IN
    Biol Psychiatry; 1991 Feb; 29(4):357-64. PubMed ID: 1674664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides in the neocortex in Alzheimer's disease and ageing.
    Ferrier IN; Leake A
    Psychoneuroendocrinology; 1990; 15(2):89-95. PubMed ID: 1972799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of peptide metabolism and neuropeptidase activity in senile dementia of the Alzheimer's type.
    Waters SM; Davis TP
    Ann N Y Acad Sci; 1997 Apr; 814():30-9. PubMed ID: 9160957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptides in aging and dementia.
    Joynt RJ; McNeill TH
    Peptides; 1984; 5 Suppl 1():269-74. PubMed ID: 6148737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of neuropeptides in neurological diseases.
    Sagar SM; Beal MF; Marshall PE; Landis DM; Martin JB
    Peptides; 1984; 5 Suppl 1():255-62. PubMed ID: 6207511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of region-specific alterations of neuropeptidase content on the catabolic fates of neuropeptides in Alzheimer's disease.
    Ichai C; Chevallier N; Delaere P; Dournaud P; Epelbaum J; Hauw JJ; Vincent JP; Checler F
    J Neurochem; 1994 Feb; 62(2):645-55. PubMed ID: 7905027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.
    Chan-Palay V; Asan E
    J Comp Neurol; 1989 Sep; 287(3):373-92. PubMed ID: 2570794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.
    Chan-Palay V
    J Comp Neurol; 1988 Jul; 273(4):543-57. PubMed ID: 2463283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.
    Hoyer D; Bartfai T
    Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptides in learning and memory.
    Borbély E; Scheich B; Helyes Z
    Neuropeptides; 2013 Dec; 47(6):439-50. PubMed ID: 24210137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuropeptides in Alzheimer's disease].
    Jiménez-Corral C; Morán-Sánchez JC; Alonso-Navarro H
    Rev Neurol; 2006 Mar 16-31; 42(6):354-9. PubMed ID: 16575772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptides in the sympathetic system: presence, plasticity, modulation, and implications.
    Benarroch EE
    Ann Neurol; 1994 Jul; 36(1):6-13. PubMed ID: 8024263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of neuropeptides on cognitive function.
    Bennett GW; Ballard TM; Watson CD; Fone KC
    Exp Gerontol; 1997; 32(4-5):451-69. PubMed ID: 9315449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptides and neurotransmitters in Alzheimer's disease: focus on corticotrophin releasing factor.
    Doraiswamy PM; Krishnan KR; Nemeroff CB
    Baillieres Clin Endocrinol Metab; 1991 Mar; 5(1):59-77. PubMed ID: 1674857
    [No Abstract]   [Full Text] [Related]  

  • 17. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia.
    Oram JJ; Edwardson J; Millard PH
    Gerontology; 1981; 27(4):216-23. PubMed ID: 6116646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropeptide processing in pathophysiology.
    Stewart JM; Hall ME
    Agents Actions Suppl; 1993; 42():211-26. PubMed ID: 8356926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropeptides: relevance in treatment of depression and anxiety disorders.
    Madaan V; Wilson DR
    Drug News Perspect; 2009; 22(6):319-24. PubMed ID: 19771321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytochemical detection of cholecystokinin and corticotrophin-releasing hormone neuropeptides in the hypothalamic paraventricular nucleus of the jerboa (Jaculus orientalis): modulation by immobilisation stress.
    Barakat Y; Pape JR; Boutahricht M; El Ouezzani S; Alaoui A; Chaigniau M; Tramu G; Magoul R
    J Neuroendocrinol; 2006 Oct; 18(10):767-75. PubMed ID: 16965295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.